Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 358

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 358
---
 option grants that are terminated or forfeited will again be available for issuance under the
2024 Plan. As of the date of this proxy statement/prospectus, there are no options or other grants outstanding under the 2024 Plan, except
that the Company entered into employment agreements with executives and compensation arrangements with prospective Board members that
provide for options for an aggregate of 360,000 shares in the event the Company completes an initial public offering of its stock.

Compensation of Directors

Dr. Sheinerman
is DiamiR’s sole director. DiamiR currently does not have a policy to pay its director for serving on its board or fees for attending
scheduled and special meetings of its board of directors.

<div align='center'>206

COMPANY TRANSACTIONS WITH RELATED PERSONS</div>

The following discussion is
a brief summary of certain material arrangements, agreements and transactions Company has with related parties since January 1, 2022,
other than the compensation and shareholding arrangements that are described in “Management” and “Principal Shareholders.”
We also engage in other transactions with related parties that we do not perceive as material.

Lines of Credit

On August 13, 2019 (the “Effective
Date”), Aptorum Therapeutics Limited (“ATL”), one of our wholly owned subsidiaries, entered into two separate Promissory
Notes and Line of Credit Agreements (the “Agreements”) with Aeneas Group Limited and Jurchen Investment Corporation (“Jurchen”).
The Aeneas Group Limited Agreement and Jurchen Agreement provide ATL with a line of credit up to twelve million dollars ($12,000,000)
and three million dollars ($3,000,000), respectively (collectively, the “Line of Credit”), representing the maximum aggregate
amount of the advances of funds from the Line of Credit that may be outstanding at any time under the Line of Credit (the “Principal
Indebtedness”). ATL may draw down from the Line of Credit at any time through the day immediately preceding the third anniversary
of the Effective Date (the “Maturity Date”). As of the date hereof, the Jurchen Agreement is matured, and the maturity of
Aeneas Group Limited Agreement is extended for additional three years and will be matured on August 12, 2025. Interest is payable on the
outstanding Principal Indebtedness at the rate of eight percent (8%) per annum, payable semi-annually in arrears on